2016). Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.
Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist ¶ ¶ | | | | inoculated into 96 well plates containing 500 µl of BMGY and grown at 30 ºC for 24 hr (covered with a sterile breathable seal). Each plate contained a set of controls, including non transformed cells and cells secreting domain11 WT , domain 11 AB3 and domain 11 I1572A mutants.
The medium was replaced with BMMY and induction was sustained by supplementing with methanol to a final concentration of 1% (v/v) every 24 hr for two days.
Supernatants (100 µl) containing the secreted domain 11 mutants, were transferred to a 96 well plate, diluted with 100 µL of HBS-EP (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20) and screened for IGF2 binding ability by SPR on a Biacore 3000. Biotinylated IGF2 (GroPep, Aus) was immobilized on the flow cells of the sensor chip SA by affinity capture to streptavidin. Kinetic experiments were performed at 25 ºC in HBS-EP at a flow-rate of 40 µL min -1 and consisted of a 2 min injection of diluted supernatant followed by a 2 min dissociation phase in HBS-EP running buffer, after which the binding surface was regenerated with a 2 min injection of 2M MgCl 2 . The resulting sensorgrams were visually analysed using the standard BiaEvaluation software version 4.0.1
for Biacore 3000. Additionally, the dissociation phase was fitted to a first order exponential decay curve (Y=Y 0 ·e -k off. x ) from which the k off could be calculated.
Protein expression and purification of M6P/ IGF2R domain 11 mutants for SPR studies.
For expression, yeast colonies selected on MD plates were grown at 30 ºC in 10 mL of BMGY for 24 hr and induced by being transferred to 50 mL BMMY. For maintained induction, cultures were supplemented with methanol to a final concentration of 1% (v/v) every 24 hr for two days. Supernatants were then subjected to SDS-PAGE and western blot using anti-His 6 mouse monoclonal antibody conjugated to peroxidase (Roche Diagnostics, USA). Domain 11 secreting cultures were scaled up to 500 mL BMMY and grown for further 72 hr and supplemented with 1% methanol every 24 hr. Supernatants were cleared by centrifugation (6000rpm for 20 min at 4 ºC in a Beckman-Coulter Avanti-J2 refrigerated centrifuge), diluted 5-fold in 20 mM sodium phosphate pH 8.0 buffer and His-purified using a Ni-NTA superflow column (Qiagen) on an Äkta FPLC system (GE Life Sciences, UK)
washed with 50 mM imidazole and eluted with 250 mM imidazole. The fractions containing the protein were pooled and, when required, diluted in 20 mM MES pH 6.0 and purified using a Resource S column on an Äkta FPLC system (GE Life Sciences, UK). Purified proteins were dialyzed and concentrated using centrifugal filter units of 5 kDa cut-off (Millipore). Protein concentration was determined spectrophotometrically (Nanodrop) using Functional evolution of IGF2:IGF2R domain 11
the theoretical extinction coefficient calculated by ProtParam and protein size and homogeneity was verified using 12% SDS-PAGE.
Structure-informed loop-specific site directed mutagenesis.
The domain 11 AB3 :IGF2 structure (PDB: 2L29) was used to identify residues in the binding loops that could interact with IGF2. These were manually mutated in Pymol v1.5 to determine whether or not they might stabilise the complex (http://www.pymol.org/). In addition the Robetta server (http://robetta.bakerlab.org/alascansubmit.jsp) was used to perform interface alanine scanning mutagenesis on the Domain11 AB3 complex to identify residues important for complex formation. A number of possible amino acids were introduced at each site to assess the residue's role in binding. M6P/IGF2R domain 11 sub-cloned from the pPICHis vector into pET26a (Novagen, Merck Chemicals Ltd, Nottingham, UK) was used as a template for site directed mutagenesis. The template was amplified in a thermocycler (PeqStar) using mutagenic primers and KOD DNA polymerase (Novagen) to introduce the mutations. Following amplification the parental DNA was digested with DpnI and transformed into E. coli 5α cells (NEB) for sequencing. The mutant proteins were expressed and refolded using existing protocols in E. coli BL21 (DE3) before the binding kinetics were analysed by SPR (5) .
Expression and purification of domain 11 WT , domain 11 AB5 and IGF2-domain 11 AB5 complexes for NMR.
His 6 -tagged domain 11 WT and domain 11 AB5 (residues 1508-1654) cloned into pET26 (Novagen, Merck Chemicals Ltd, Nottingham, UK) were transformed into E. coli BL21(DE3)
CodonPlus™ competent cells, purified as inclusion bodies and refolded according to wellestablished protocols (5) . Proteins were isotopically labelled using 1 g L -1 15 N-ammonium chloride and/or 2 g L -1 13 C 6 -glucose (99%, Cambridge Isotope Laboratories) in M9 minimal media. Lyophilised IGF2 (Novozymes Biopharma, AU) was added to NMR samples of 15 Nsingle (dynamics studies) and 15 N, 13 C-double labeled domain 11 AB5 mutant (structural studies) in a 1:1 ratio at pH 4, which provided optimum stability for the complex. Structural calculations of the domain 11 AB5 both free and complexed with IGF2 were as described for the domain 11 AB3 :IGF2 complex (5 those experiments with NOE. Data collected was processed (NMRPipe, (7) ) and assigned (Analysis 2.1.5 (8)) before being exported for curve fitting and model free analysis (relax 1.3.9 (9, 10) . Relaxation rates were calculated by an eleven parameter grid search, followed by simplex minimisation curve fitting to a two-parameter (I 0 , R x ) exponential decay. Monte
Carlo error analysis used the standard deviation of simulated curves back calculated from fitted parameters across replicated spectra, or from the Sparky 3.113 (Goddard T. D.), with RMSD calculation of noise in a peak-free region of non-replicated spectra. Relaxation datasets recorded at 600 and 900 MHz were validated using self-consistency tests within relax (See Supplementary Figure 3 ). Extended model free analysis (11) (12) (13) was performed within relax 1.3.9 which involved AIC model-free model selection (14) and elimination of failed models followed by Monte Carlo simulations (15) . After initial calculation of local τ m values, isotropic (sphere) and anisotropic (prolate/oblate spheroids, ellipsoid) diffusion models were optimised followed by AIC selection of the best model.
Expression, purification and crystal structure of domain 11 AB5-RHH
Domain 11 AB5 Q1569R P1597H S1602H pET 26a plasmid was generated and refolded as above. Protein concentration of 2.5 mg/ml (160 µM) was used to screen for crystals in a 96 well format using Phoenix Liquid Handling System (Art Robbins Instruments) with multiple commercial buffer screens. Crystals corresponding to data collection were formed in JCSGplus TM screen, well G11 (2.0 M Ammonium Sulphate, 0.1M Bis-(2-hydroxyethyl)iminotris(hydroxymethyl methane, pH 7.0), to generate orthorhombic crystals (width:5 µm, length:
40 µM). Data collection carried out using PILATUS detector at station I04 of the Diamond synchrotron revealed that crystals were orthorhombic and belonged to space group P2 1 2 1 2 1 .
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Diffraction images were processed using automated Xia 2 pipeline at Diamond Light Source, UK. Auto processed data generated from Xia 2 yielded intensity data to medium resolution (for data statistics, molecular replacement and refinement details, see Supplementary Table 8 ).
SPR validation and binding analysis.
Kinetic analysis of mutants by SPR was conducted using a Biacore T200 biosensor at Thermodynamic data was performed across the temperature range of 10 ºC to 30 ºC, van't Hoff and Erying plots generated and ΔH, -TΔS and ΔG values determined as previously described (4).
Fc-fusion protein expression and purification.
IgG1 Fc-domain 11 AB5 fusion protein was first cloned as previously described (16), 
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Agarose beads were washed according to the manufacturer´s instructions, resuspended in 2 × sample buffer, boiled and the supernatant used for western blot analysis as described previously.
IGF2 induced hypoglycaemia.
All animal experiments were approved by the animal use ethical committee of Oxford
University and fully complied with UK Home Office guidelines (PPL 30/2695). Wild-type C57BL/6J and 129S2 mice were anaesthetised using a rising concentration of isoflurane in oxygenated air and maintained using 2% isoflurane with 2 L min -1 oxygen. Blood glucose measurements were taken using an Advantage diabetic glucose meter (Roche Diagnostics, UK), blood glucose levels were allowed to normalise for 30 min prior to taking a baseline blood glucose reading, then either 1 mg kg -1 IGF2 alone (R&D systems), or 1 mg kg -1 IGF2 premixed with 10.9-11.7 mg kg -1 Fc-domain 11 AB5 , Fc-domain 11 AB5-RHH or Fc-domain 11 I1572A (for a 1:1 molar ratio) were injected. Blood glucose measurements were taken every 10 min for the following hour. For the Fc-domain 11 AB5 mouse preloading experiment, 11.7
mg kg -1 Fc-domain 11 AB5 or PBS, as negative control, were injected immediately after induction of anaesthesia, 30 mins later a baseline blood glucose determined and IGF2 (1:1 molar ratio) injected, readings were then taken every 10 min for the following hour. For the IGF2 preloading experiment, 1 mg kg -1 IGF2 was injected immediately after induction of anaesthesia, 30 min later a baseline blood glucose reading was determined and either 11.7 mg kg -1 Fc-domain 11 AB5 (1:1 molar ratio) or PBS were injected, readings were then taken every 10 min for the following hour.
IGF2 dependent human cancer cell xenografts.
IGF2 sensitive autocrine cell lines SKNMC-IGF2 1-67 , SKNMC-FLAG-IGF2 1-67 , SKNMC-IGF2 1-104 and SKNMC-FLAG-IGF2 1-104 were generated from the Ewing sarcoma cell line SKNMC by retroviral infection with constructs containing IRES-luciferase.
Constructs were generated by cloning into the the BglII and EcoRI of the pMSCV retroviral expression vector. The constructs contained the IGF2 secretion signal, followed by the IGF2 (e.g. with and without the FLAG-tag and R67STOP/ R104STOP truncated coding sequence)
IRES and the Luc2 gene. Retrovirus were packaged by transfection of constructs with
TransIT-X2 (Mirus) into Phoenix cells, medium was collected after 48 h, filtered (0.45 µm)
and replaced the medium of SKNMC cells with polybrene (6-8 µg/ml). After 48hr, the transfection medium was removed from target cells and transduced cells were selected with fresh medium containing 2 µg/ml of puromycin.
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Autocrine growth and signaling function of SKNMC lines, including inhibition by IGF2-TRAP, were confirmed in culture using an MTS reagent (Cell Titer 96 Aqueous One Solution cell proliferation assay, Promega). For xenografts, approximately 5x10 6 SKNMC-IGF2 1-67 cells harvested during the growth phase of sub-confluent cell cultures were then mixed with matrigel (50:50 v/v, 100µl/ mouse) and injected (sub-cutaneous) into CD-1 ® (Crl:NU-1 Foxn1 nu ) female mice, 24 hours after establishing ALZET® mini-pump placement delivering a single concentration 40mg kg -1 per week either IGF2-TRAP or PBS vehicle control.
Tumour growth was monitored with both caliper measurements and bioluminescence. The latter was performed with a Bruker Xtreme 2D optical system 15 minutes (10 second exposure) following luciferin injection (100 µl per 20g body weight).
Tumours were excised at 28 days or when size was > 1000 mm 3 . Fixation in formalin, embedding in paraffin and Hematoxylin and Eosin (H&E) staining was done using standard protocols. Apoptotic area was quantified using automated image analysis of brightfield images in ImageJ, applying H AEC color de-convolution filter and automated thresholding.
Serum was also collected at the time of culling.
IGF2-TRAP synthetic lethality screens.
For synthetic lethality screens (Target Discovery Institute, University of Oxford), either 2,500 or 5,000 SKNMC-IGF2 1-104 -IRES-luc cells were plated in medium containing 0.5% charcoal stripped FBS in 384 well plates and the IGF2-TRAP was added 24h later to half of the plates. Using automated dispensing, 307 oncology drugs that have been tested in man (TDI expanded OncologyDrug library) were added to cells 3hrs later at 10 µM, 1 µM, 100 nM and 10 nM, in the presence and absence of 250 nM IGF2-TRAP. After 48hr of incubation, resazurin was added to a final concentration of 10 µg/mL and the fluorescence (Ex: 560 nm, Em: 590 nm) recorded at 2hr. Normalisation was performed with untreated cells and cells treated with the fixed concentration of IGF2-TRAP alone. Pearson's productmoment correlation coefficient (r) was calculated to determine replicate correlation. For hit selection, we used a bespoke 'interaction score' metric (a variation on standard ∆z-score analysis) followed by hit selection using the robust non-parametric Rank Product method (17) .
The interaction score was calculated where ! was the viability readout for the drug condition, ! was the sample mean of the negative controls and ! was the sample standard the degree of inhibition of cell viability by 'drug d ± IT' relative to negative controls, also taking into account well-to-well variation. The interaction score is defined as
Thus, a more negative interaction score represents a greater synergistic lethal effect: the inhibitory effect of the drug is potentiated by IT. Interaction scores were calculated for each
The rank product was calculated in each data set (16 data sets: cell density x drug library concentration x rezasurin incubation time) each replicate for each drug was ranked independently, with 1 st rank assigned to the most negative interaction score. Using these ranks, a Rank Product!!" ! for drug d in each data set was calculated, where ! !,! is the rank of the ith replicate for drug !:
In a permutation test, the RP for each drug is compared to a simulated data set giving an (R&D Systems MAB775, 1 µg mL -1 ), anti mIGFBP5 (R&D Systems AF578, 0.1 µg mL -1 ), anti mIGFBP6 (R&D Systems AF776, 0.1 µg mL -1 ), anti mGH (R&D Systems BAF1566, 0.5
µg mL -1 ), anti hIGFBP3 (Santa Cruz Biotechnology Sc-9028, 1 µg mL -1 ), anti hALS (Novus Biologicals NBP1-89118, 1 µg mL -1 ). Secondary antibodies were from Dako, used at 1:2000, except Streptavidin HRP at 1:4000 (Thermo Scientific Pierce). Densitometry was performed using ImageJ (NIH) and was normalized to actin.
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Supplementary Tables
Supplmentary Table 1 Loop libraries. Mutated residues in each loop are shown in bold, Sequences of the forward and reverse oligonucleotide primer pairs used for site-directed mutagenesis to generate domain 11 loop specific libraries are shown. One oligo in each pair was 5'-phosphorylated (indicated with *). XXX indicates an equal amount of codons encoding each one of the 19 possible amino acids (Cys was excluded). Functional evolution of IGF2:IGF2R domain 11 Supplementary Table 5 Structure quality statistics for domain11 WT , domain 11 AB5 and domain 11 AB5 :IGF2 complex
Mutant loop
Ramachandran plot regions and iCing Z-scores for the lowest energy structure and ensemble for domain 11 WT , domain 11 AB5 and its complex with IGF2. Structure Z-scores above zero are better than average. RMS Z-scores should be close to 1. Human ensemble results were recalculated using NRG-CING (20) . Best refers to the best statistics selected for one model within the ensemble. R free is as for R factor but calculated using a 5% test set of reflections excluded from the refinement. Data collection carried out using PILATUS detector at station I04 of the Diamond synchrotron revealed that crystals were orthorhombic and belonged to space group P2 1 2 1 2 1 . Diffraction images were processed using automated Xia 2 pipeline. Auto processed data generated from Xia 2 yielded intensity data to medium resolution. Processing was carried out using programs in the CCP4 suite (21) . Phaser MR (22) was used in molecular replacement (MR) with a known structure (PDB:1GP0) for domain11 WT to generate a MR solution. The crystals contained a single domain 11 AB5-RHH monomer per crystallographic asymmetric unit; the same as 1GP0. Structural refinement was then carried out using refmac5 (23) . Further refinement was undertaken, with the rebuilding of the AB loop from WT to AB5, the introduction of residues Q1569R, P1597H and S1602H and other manual rebuilding performed using COOT (24) . Structural model built was then validated using PROCHECK (25) , MolProbity (26) , and PDB_REDO server (27) . Supplementary Table 9 Affinity of IGF2 isoforms (IGF2 1-67 , IGF2 1-104 and IGF2 1-156 ) and IGF1 for the Fc-domain 11 AB5 , Fc-domain 11 AB5-RHH and Fc-domain 11 I1572A fusion proteins. SPR analysis of the interaction of recombinant IGF1 and IGF2 forms with Fc-domain 11 proteins immobilised by antibody capture (CM5 chip containing monoclonal mouse anti-human IgG antibody immobilised by amine coupling). Measurements were carried out at 25 o C in HBS-EP buffer (pH 7.4). Example sensorgrams are shown in Fig. 5A . 
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---* Note, kinetic analysis may be inaccurate because of uncertainties in the concentration of recombinant IGF2 1-156 (Gropep). This consisted of a mixture of three isoforms, the full-length protein and truncated peptides (151 and 141 residues long).
Supplementary Figures
Background to Supplementary Figures S1-4 Relaxation data analysis for domain 11 WT and domain 11 AB5 . NOE, R 1 and R 2 relaxation datasets were recorded for domain 11 WT and domain 11 AB5 and are shown in Supplementary Fig. 2a-f . NOE ratios, which are sensitive to fast picosecond motions, are shown at both 600 and 900 MHz for domain 11 and domain 11 AB5 ( Supplementary Fig. 1a, 1b) . NOE values above 0.7 (indicating more ordered regions of protein structure) were generally located in β-strand secondary structure of the β-barrel in both proteins as previously observed for domain 11 WT (5) . The AB, CD, FG and GH loop regions and termini had lower NOE ratios indicating the presence of faster ns-ps motions. The most flexible loops in domain 11 WT were the AB and GH loops with significantly reduced values seen in both. In domain 11 AB5 however, the AB loop NOEs does not show the same degree of reduction. Flexibility in the isolated domain 11 WT AB and GH loops are might be expected due to removal of the neighbouring domain 13 that is observed to pack against it in the X-ray structure (28) . The FG loop shows reduced NOE values in both proteins whereas the CD loop appears to show only marginally lower values. These differences are also reflected in the R 1 values with domain 11 AB5 showing almost uniform values across the entire peptide compared to domain 11 WT which whose elevated R 1 values across the loops with reduced NOE values. With the exception of the FG loop, R 2 values across domain 11 AB5 are reduced compared to the wild type human protein.
Validation of domain 11 WT and domain 11 AB5 relaxation datasets.
R 1 and R 2 relaxation rates were validated by calculation of 900:600MHz ratios for each parameter ( Supplementary Fig. 2 ). R 1 values were more consistent than R 2 values due better signal to noise in these experiments. R 1 (900)/R 1 (600) and R 2 (900)/R 2 (600) ratio averages ( Supplementary Fig. 2a-d ) and standard deviations were comparable between the two proteins. R 1 (900)/R 1 (600) ratios were 0.65 ± 0.07 for human wild-type and 0.64 ± 0.05 for domain 11 AB5 . R 2 (900)/R 2 (600) ratios were 1.30 ± 0.22 for domain 11 and 1.17 ± 0.29 for domain 11 AB5 . R 2 /R 1 ratios were calculated at 600 (black) and 900 (white) MHz ( Supplementary Fig. 2e-f ) with lines marking the mean for each field. 900:600MHz ratios deviating form the average and yielding a non-linear correlation between R 2 /R 1 and field strength, were excluded from subsequent Lipari-Szabo model-free calculations. An average of the three consistency test results is shown for domain 11 WT (Supplementary Fig. 2g ) and domain 11 AB5 ( Supplementary Fig. 2h ). For all tests, a parameter ratio 900/600 MHz close to 1 represented data which was consistent between fields. Results were more consistent for domain 11 (0.98 ± 0.21) versus 1.07 ± 0.16 for domain 11 AB5 . Fη, F R2 (29) and J(0) (30)consistency tests provided with RELAX used NOE ratio, and R 1 and R 2 relaxation rates (31) are shown in Supplementary Fig. 3a -l. Distributions (panels df for domain 11 versus j-l for domain 11 AB5 ) for both proteins are within a range of values previously described (31) (32) (33) . Any values that severely deviated from a 900:600MHz ratio of 1 were removed before input of parameters into relax for application of the Lipari-Szabo model-free formalism.
Lipari-Szabo model-free calculations for domain 11 WT and domain 11 AB5 .
Lipari-Szabo parameters for isotropic (spherical) and anisotropic models (oblate, prolate and ellipsoid) were best fit in RELAX by oblate and fully anisotropic models for domain 11 WT and domain 11 AB5 respectively. Residues that passed internal consistency tests were used in the calculation of the global rotational correlation time that was determined to be 7.62 ns for domain 11 WT and 8.19 ns for domain 11 AB5 . This is consistent with a negligible effect on the oligomeric state of the protein and the overall tumbling rate in solution. Residues were fit to one of five models. These included model 1, where the backbone motion could be described by the generalized order parameter S 2 only, model 2 that incorporates S 2 and a contribution from faster picosecond motions characterized by a second correlation time τ e (S 2τ e ) and models 3 and 4 that incorporate an additional slower (typically µs-ms) exchange contribution (R ex ) and described by S 2τ e and S 2τ e -R ex respectively. Fits to these models are shown in Supplementary Fig. 4a -c. Domain 11 WT flexible AB, BC and CD loops, shown by S 2 values below 0.7. These loop regions are much more rigid in domain 11 AB5 , consistent with NOE, R 1 and R 2 data. This suggests that the ring-stacking interactions of Y1542, W1546 and F1567 could reduce flexibility in the AB, BC and CD loops, stabilising the docking site of IGF2. Internal correlation times (τ e ) also reveal values of ~ 1ns that are present in the β-cap, pre-AB loop strand, AB, CD, FG and GH loops of domain 11 WT that are not observed in domain 11 AB5 . Similarly greater contributions from slower exchange are observed in the β-cap, AB, BC, CD, FG and GH loops in domain 11 WT . In domain 11 AB5 these again appear to be lost with the exception of the FG loop, which is unaffected.
Residues that could not be defined by these simpler models were also fitted to a twotime-scale model (34) , an extension of the original Lipari-Szabo formalism that incorporates both fast picosecond (S 2 f , τ f ) and slow, sub-nanosecond (S 2 s , τ s where S 2 = S 2 f S 2 f ) contributions to the overall correlation function for the amide bond vector. S 2 f , S 2 f , τ f , τ s , parameters are shown in Supplementary Fig. 4d -g. Residues 1539-1541 and 1547 in domain 11 display lower S 2 f values, mirroring the reduction in S 2 seen in the AB loop whereas residues 1544-1546 instead show lower S 2 s values which still indicates flexibility but on a slower timescale and may reflect their proximity, and packing, against the the more rigid CD loop. In domain 11 AB5 both fast and slow motions are lost in the AB loop emphasizing the importance of the G1546Q mutation in stabilizing the binding site of this mutant. Comparison of thermodynamic parameters for domain 11 mutants and combinations. Surface plasmon resonance was performed with domain 11 mutants and immobilised IGF2 over a range of temperatures (10 °C to 30 °C ), van't Hoff and Erying plots generated and ΔH, -TΔS and ΔG values determined. Plots of ΔH, -TΔS and ΔG for free proteins (A+B), transition state (A-B) and complex (AB) for indicated mutants.
Supplementary Figure S7 .
Fc-domain 11 AB5 and Fc-domain 11 AB5-RHH fusion protein expression and purification
(a) HEK293T cells were grown in DMEM (10 % FCS and Penicillin/Streptomycin) in a 10L CellStack, transfected with polyethyleneimine (PEI) stock (1 mg/ml, pH 8.0; branched 25kDa PEI, Sigma-Aldrich) with gentle mixing. Following incubation for 4 days, cell supernatant was harvested, clarified by centrifugation (8000g for 30min at 4 °C) and filtration through a 0.45 µM membrane (type HAWP, Millipore) using a vacuum pump and bottle-top filtration unit (Nalgene). Purification was in two stages; initial capture by affinity chromatography followed by ion exchange. Capture was by HiTrap rProtein A FF column (GE Healthcare) pre-equilibrated with 20 mM sodium phosphate pH 7.0 and elution was with 0.1 M sodium citrate pH 3.5 with neutralisation by 0.1 volumes of 1 M Tris pH 9.0. Cation exchange was with a MonoS 5/50GL column (GE Healthcare) pre-equilibrated with 50 mM sodium phosphate pH 7.4 and elution by steep sodium chloride gradient (left panel). Size Exclusion Chromatography was performed with a Superose 6 10/300GL analytical column, pre-equilibrated with 150 mM sodium chloride 50 mM sodium phosphate pH 7.0 (right panel). (b) Purity and specificity were assessed by SDS-PAGE followed by Coomassie staining or western blotting utilising HRP-conjugated anti-Fc antibody (goat polyclonal; Sigma-Aldrich) or HRP-conjugated anti-His tag antibody (Clone BMG-His-1; Roche) as probes. (c) Stable CHOK1SV GS-KO cells were cultured (Lonza proprietary media, 4-10L) in a shaking incubator (140rpm) as described in material and methods. After 7 days, clarified supernatant was purified using a HiTrap MabSelect SuRe column (GE Healthcare), washed and protein eluted with 10mM formate, pH 3.5, and neutrolised with sodium hydroxide. SE-HPLC of the protein (shown) was with a Zorbax GF-250 column (Agilent). 
